GIO Therapeutics stands at the forefront of medical innovation, specialising in the development of G protein-coupled receptor (GPCR)-targeted pharmaceuticals. Our innovative approach positions us to address complex challenges in oncology and inflammatory diseases. Our focus is not only to discover; our aim is to significantly improve patient outcomes. This bold vision, together with our commitment to groundbreaking research, makes GIO Therapeutics a leader in the field. Our strategic approach to drug development positions us as a compelling opportunity in a rapidly evolving field.
GIO Therapeutics is a proud venture of Cumulus Oncology.
At GIO Therapeutics, our strength lies in our team. Each member brings a unique set of skills and experiences, all united by a shared passion for oncology drug discovery and a history of building and creating successful companies.
Tilly Bingham brings a rich tapestry of experience from the pharmaceutical and biotech worlds. With a solid foundation in chemistry, her expertise is vast, covering areas from company establishment to intricate project management and innovative product development. Tilly's proven ability to craft strategic roadmaps and metamorphose fresh ideas into impactful products will be crucial for GIO Therapeutics.
A seasoned financial executive with a strong track record in driving financial strategies and operational excellence. Proven ability to navigate complex financial landscapes and deliver strategic solutions sets him apart as a trusted leader in the industry.
Specialising in oncology and target validation, Dr. Nikki March boasts over two decades of experience in the field. Her expertise delves deep into molecular signaling and signal transduction pathways, with a significant emphasis on their application in drug discovery. Nikki's unparalleled skills in target identification and validation will be pivotal to GIO's research and development endeavors.
Clare Doris has built a distinguished career founding and managing companies within the oncology sector. Her strategic vision and leadership have been pivotal in the growth of numerous successful ventures. As the current COO of Cumulus, Clare's ambitious expansion plans are backed by her vast experience and sharp business acumen. Her guidance will be indispensable to the successful launch and growth of GIO Therapeutics.
Tim Sparey's career spans a remarkable 28 years across blue-chip big pharma, specialty pharma and biotech. Having held C-suite and chair roles including CEO and CBO, Tim is primed to offer his expertise to GIO. With total deal values worth over $6bn, his insights and experience promise will help shape the company's business strategies and operations.
Thomas Wirth brings a treasure trove of experience from the therapeutic and biotech industry. His expertise spans a vast range, from founding firms to managing intricate projects and pioneering innovative products. Thomas has a proven knack for defining roadmaps and transforming novel ideas into strategic products, making him a valuable asset to GIO Therapeutics.
Experienced in academia, pharma, and CROs, specialising in oncology and immunology research. Skilled in managing early-stage preclinical projects, with expertise in novel immuno-oncology targets to redirect the immune system against tumours.
Specialising in medical genetics, Daragh Campbell has played a pivotal role in drug discovery and research for both oncology and anti-aging companies. Her work seamlessly bridges the gap between scientific innovation and commercial strategy, offering vital support to executive and commercial teams.
At GIO Therapeutics, we believe in the power of collaboration to drive innovation and achieve groundbreaking results in oncology. Our commitment to pioneering the future of oncology is strengthened when we join forces with like-minded professionals and organisations.
If you possess an asset, target, or unique expertise that aligns with our mission, we invite you to connect with us. Together, we can explore the potential of our combined strengths.
For investors keen on being part of our journey and eager to learn more about our endeavours, we welcome the opportunity to discuss our vision, progress, and the promising future ahead.